Posts tagged ‘Ipilimumab’
August 25th, 2011
Last week the hot news was the anticipated FDA approval of vemurafenib (Zelboraf™) in metastatic melanoma for patients with BRAF V600E mutations.
“the good news is that oncologists now have two new agents for treatment in 2011, which is very much a grand cru year for melanoma.”
A little known fact is that Sally is a former finalist in the UK Daily Telegraph newspaper’s wine taster of the year competition, so it is perhaps not surprising to see some wine references in her writing.
If you are interested in the price of Zelboraf™ – you can find it on Pharma Strategy Blog where Sally analyses the cost of a course of treatment and compares this to the price for ipilimumab.
Pieter Droppert’s write-up of the 2011 ASCO annual meeting plenary data on metastatic melanoma was recently published in the august issue of Pharmacy Today.
May 31st, 2011
This Friday sees the start of the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The meeting runs from June 3-7.
On Pharma Strategy Blog, Sally Church shares her thoughts on what she expects to be hot news at ASCO this year.
In her ASCO11 video preview Sally discusses clinical trial presentations in ovarian cancer, metastatic melanoma and soft tissue sarcoma. You can watch Sally’s video below and read more on Pharma Strategy Blog.
Icarus Consultants will be attending ASCO (along with 30,000 others), so if you are interested in meeting up, please contact us.
May 18th, 2011
The data from this study was presented in Tuesday’s plenary session by Dr Tim Wilt, a Professor at the University of Minnesota, and was to many attendees, the highlight of the meeting.
The trial results showed for the first time that radical prostatectomy (RP) is no better than watchful waiting in men with early stage prostate cancer using evidence based medicine.
This groundbreaking research is likely to have a major impact on urology practice in the United States.
Pieter Droppert wrote about the PIVOT results on Biotech Strategy Blog. Scott Hensley on NPR’s Health Blog, “Shots” references Pieter’s post, and has an interview with Dr Wilt that is also well worth reading.
Also presented at AUA in Tuesday’s plenary session were the results from:
This study looked at castrate resistant prostate cancer patients at high risk of development of bone metastasis.
Sally Church on Pharma Strategy Blog discusses the results presented by Dr Matthew Smith at AUA. Denosumab was shown to increase bone metastasis-free survival and delayed time to first bone metastasis, but did not increase overall survival (OS).
Both Sally Church and Pieter Droppert also wrote additional blog posts from the meeting. On Biotech Strategy Blog, Pieter wrote about data that showed:
He also wrote about:
Some of the new products mentioned in Pieter’s post include alpharadin, XL-184 (cabozantinib), Prostvac-VF, BPX-101 and ipilimumab. You can read more on Biotech Strategy Blog.
Meanwhile on Pharma Strategy Blog, Sally Church continued one of her themes of how social media is impacting medical conferences by reviewing:
Sally also recorded a video blog post (vlog) from AUA that highlighted some of the exciting developments in basic biology and how this may lead to new Prostate Cancer treatments in the future. Click here to watch this.
If you were unable to attend the meeting, Sally aggregated the #AUA2011 tweets.
Selecting what to write about on a blog is subjective, so the above posts are not intended to provide comprehensive meeting or conference coverage, only a few highlights of what was presented at the highly informative and educational AUA annual meeting.
If you are interested in a more comprehensive report on the Prostate Cancer Market and the emerging new products in development, please do not hesitate to contact us.